David A. Siegel Outlook Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.87 - $1.33 $127,716 - $195,244	-146,800 Reduced 74.71%	49,700 $53,000
Q3 2022 Nov 14, 2022	SELL	$1.02 - $1.26 $156,672 - $193,536	-153,600 Reduced 43.87%	196,500 $240,000
Q2 2022 Aug 15, 2022	SELL	$0.91 - $2.01 $173,992 - $384,311	-191,200 Reduced 35.32%	350,100 $357,000
Q1 2022 May 16, 2022	SELL	$1.22 - $2.03 $426,634 - $709,890	-349,700 Reduced 39.25%	541,300 $964,000
Q4 2021 Feb 14, 2022	BUY	$1.27 - $2.23 $737,997 - $1.3 Million	581,100 Added 187.51%	891,000 $1.21 Million
Q3 2021 Nov 15, 2021	SELL	$2.12 - $2.76 $818,108 - $1.07 Million	-385,900 Reduced 55.46%	309,900 $672,000
Q2 2021 Aug 16, 2021	BUY	$1.78 - $2.76 $164,650 - $255,299	92,500 Added 15.33%	695,800 $1.73 Million
Q1 2021 May 17, 2021	BUY	$0.94 - $3.31 $432,118 - $1.52 Million	459,700 Added 320.13%	603,300 $1.36 Million
Q4 2020 Feb 16, 2021	SELL	$0.7 - $1.58 $2,940 - $6,636	-4,200 Reduced 2.84%	143,600 $187,000
Q3 2020 Nov 16, 2020	BUY	$0.61 - $1.6 $90,158 - $236,480	147,800 New	147,800 $106,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $536M
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.